CNS Pharmaceuticals (CNSP) vs Longeveron (LGVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Longeveron is the larger company by market cap ($7.9 million vs $7.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSP | LGVN |
|---|---|---|
| Share price | $5.35 | $2.48 |
| Market cap | $7.82M | $7.91M |
| 1-day change | 0.00% | +4.64% |
| EPS (TTM) | $-17.90 | $-9.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.54 | $12.30 |
| 52-week low | $1.90 | $2.30 |
| Distance from 52-week high | -49.24% | -79.84% |
| Analyst consensus | none | none |
| Avg. price target upside | +86.92% | +2369.76% |
| Average volume | 6.36K | 93.11K |
| Shares outstanding | 1.46M | 3.04M |
| Employees | 8 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CNS Pharmaceuticals
CNSP stock →CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Longeveron
LGVN stock →Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
CNSP vs LGVN FAQ
Which is bigger, CNS Pharmaceuticals or Longeveron?
Longeveron (LGVN) is larger, with a market capitalization of $7.91M compared with $7.82M for CNS Pharmaceuticals (CNSP).
Are CNS Pharmaceuticals and Longeveron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.